Technical Analysis for IKT - Inhibikase Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Up |
| Historical IKT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Calm After Storm | Range Contraction | 5.26% | |
| Lower Bollinger Band Walk | Weakness | 5.26% | |
| Wide Bands | Range Expansion | 5.26% | |
| Lower Bollinger Band Touch | Weakness | 5.26% | |
| New 52 Week Closing Low | Bearish | 10.09% | |
| Lower Bollinger Band Walk | Weakness | 10.09% | |
| New 52 Week Low | Weakness | 10.09% | |
| Below Lower BB | Weakness | 10.09% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Inside Day | about 4 hours ago |
| 60 Minute Opening Range Breakout | about 7 hours ago |
| Rose Above 10 DMA | about 7 hours ago |
| Up 5% | about 7 hours ago |
| 10 DMA Resistance | about 7 hours ago |
Get a Trading Sidekick!
- Earnings date: ???
Inhibikase Therapeutics, Inc. Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Parkinson's Disease Neurological Disorders Stage Pharmaceutical Psychiatric Diagnosis Dementia Treatment Of Parkinson's Disease Aging Associated Diseases Neurodegenerative Disorders Pyridines Related Disorders Imatinib Lewy Body Dementia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.8 |
| 52 Week Low | 2.03 |
| Average Volume | 899,492 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 3.64 |
| 20-Day Moving Average | 2.53 |
| 10-Day Moving Average | 2.38 |
| Average True Range | 0.26 |
| ADX | 36.7 |
| +DI | 12.54 |
| -DI | 28.23 |
| Chandelier Exit (Long, 3 ATRs) | 2.14 |
| Chandelier Exit (Short, 3 ATRs) | 2.82 |
| Upper Bollinger Bands | 2.90 |
| Lower Bollinger Band | 2.16 |
| Percent B (%b) | 0.33 |
| BandWidth | 29.38 |
| MACD Line | -0.34 |
| MACD Signal Line | -0.40 |
| MACD Histogram | 0.0611 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.73 | ||||
| Resistance 3 (R3) | 2.70 | 2.56 | 2.68 | ||
| Resistance 2 (R2) | 2.56 | 2.48 | 2.58 | 2.66 | |
| Resistance 1 (R1) | 2.48 | 2.42 | 2.52 | 2.51 | 2.64 |
| Pivot Point | 2.34 | 2.34 | 2.36 | 2.36 | 2.34 |
| Support 1 (S1) | 2.26 | 2.26 | 2.30 | 2.29 | 2.16 |
| Support 2 (S2) | 2.12 | 2.20 | 2.14 | 2.14 | |
| Support 3 (S3) | 2.04 | 2.12 | 2.13 | ||
| Support 4 (S4) | 2.07 |
